Items

• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

  R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013

• Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

  B. Godman, R. Malmstrom, E. Digene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. Pedersen, V. Marković Peković, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Frontiers in Pharmacology, Vol. 5, pp. 1 - 11, Jun, 2014

• Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

  B. Godman, M. Wilcock, A. Martin, S. Bryson, C. Baumgartel, T. Bochenek, W. de Bruyn, L. Sović-Brkičić, M. D'Agata, A. Fogele, A. Coma Fuste, J. Fraeyman, J. Furst, K. Garuoliene, H. Herholz, M. Hoffman, S. Jayathissa, H. Kwon, I. Langner, M. Kalaba, E. Magnusson, E. Anderse Karlssen, O. Laius, V. Marković Peković, E. Magnusson, S. McTaggart, H. Pedersen, J. Piessnegger, A. Ringerud, G. Selke, C. Sermet, K. Schiffers, P. Skiold, D. Tomek, A. Viksna, A. Vitry, C. Zara, R. Malmstrom, Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future, Generics and Biosimilars Initiative Journal, Vol. 4, No. 3, pp. 125 - 135, May, 2015

• The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications (2017-08)

  A. Ferrario, D. Araja, T. Bochenek, T. Ćatić, D. Danko, M. Dimitrova, J. Furst, I. Greičiute-Kuprijanov, I. Hoxha, A. Jakupi, E. Laidmae, O. Loblova, I. Mardare, V. Marković Peković, D. Meshkov, T. Novakovic, G. Petrova, M. Pomorski, D. Tomek, L. Vončina, A. Haycox, P. Kanavos, P. Vella Bonanno, B. Godman, The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications, PHARMACOECONOMICS, pp. 1 - 15, Aug, 2017

• Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018-12)

  B. Godman, A. Bucsics, P. Vella Bonanno, W. Oortwijn, C. Rothe, A. Ferrario, S. Bosselli, A. Hill, A. Martin, S. Simoens, A. Kurdi, M. Gad, J. Gulbinovic, A. Timoney, T. Bochenek, A. Salem, I. Hoxha, R. Sauermann, A. Massele, A. Guerra Junior, G. Petrova, Z. Mitkova, G. Achniotou, O. Laius, C. Sermet, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, M. Oluka, H. Kwon, A. Jakupi, F. Kalemeera, J. Fadare, O. Melien, M. Pomorski, M. Wladysiuk, V. Marković Peković, I. Mardare, D. Meshkov, T. Novakovic, J. Furst, D. Tomek, C. Zara, E. diogene, J. Meyer, R. Malmstrom, B. Wettermark, Z. Matsebula, S. Campbell, A. Haycox, Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets, Frontiers in public health, Vol. 6, No. Article 328, pp. 1 - 21, Dec, 2018

• Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA (2019-02)

  P. Vella Bonanno, A. Bucsics, S. Simoens, A. Martin, W. Oortwijn, J. Gulbinovic, C. Rothe, A. Timoney, A. Ferrario, M. Gad, A. Salem, I. Hoxha, R. Sauremann, M. Kamusheva, M. Dimitrova, G. Petrova, O. Laius, G. Selke, V. Kourafalos, J. Yfantopoulos, E. Magnusson, R. Joppi, A. Jakupi, T. Bochenek, M. Wladysiuk, C. Furtado, V. Marković Peković, I. Mardare, D. Meshkov, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, A. Haycox, S. Campbell, B. Godman, Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 19, No. 3, pp. 251 - 261, Feb, 2019

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications (2019-02)

  B. Godman, A. Hill, S. Simoens, A. Kurdi, J. Gulbinovic, A. Margus, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Hoxha, C. Rodrigues, C. Hierlander, A. Malaj, R. Sauremann, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, G. Selke, J. Yfantopoulos, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. Valk, C. Hagen, A. Ringerud, R. Plisko, M. Wladysiuk, V. Marković Peković, N. Grubiša, T. Ponorac, I. Mardare, T. Novakovic, M. Parker, J. Fraeyman, D. Tomek, M. Obach Cortadellas, C. Zara, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, A. Heycox, Pricing of oral generic cancer medicines in 25 European countries; findings and implications, Generics and Biosimilars Initiative Journal, Vol. 8, No. 2, pp. 49 - 70, Feb, 2019

• Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020-02)

  B. Godman, H. McCabe, T. Leong, D. Mueller, A. Martin, I. Hoxha, J. Mwita, G. Rwegerera, A. Massele, J. Costa, R. Nascimento, L. Lovato, K. Tachkov, P. Milushewa, O. Patrick, L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, L. Achieng, A. Guantai, M. Oluka, A. Jakupi, K. Logviss, M. Hassali, D. Kibule, F. Kalemeera, M. Mubita, I. Mardare, A. Alrasheedy, J. Furst, D. Tomek, V. Marković Peković, T. Phuong, B. Thanh, A. Kalungia, T. Zaranyika, N. Masuka, I. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J. Meyer, Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 20, No. 1, pp. 1 - 26, Feb, 2020

• Variation in the prices of oncology medicines across Europe and the implications for the future (2021-02)

  B. Godman, S. Simoens, A. Kurdi, G. Selke, J. Yfantopoulos, A. hill, J. Gulbinovic, A. Martin, A. Timoney, D. Gotham, J. Wale, T. Bochenek, I. Selke Krulichova, E. Allocati, I. Hoxha, A. Malaj, C. Hierlander, A. Nachtnebel, W. Hamelinck, Z. Mitkova, G. Petrova, O. Laius, C. Sermet, I. Langer, R. Joppi, A. Jakupi, E. Poplavski, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, R. Plisko, M. Wladysiuk, V. Marković Peković, I. Mardare, T. Novakovic, M. Parker, J. Furst, D. Tomek, K. Banasova, M. Obach Cortadellas, C. Zara, C. Pontes, M. Juhasz-Haverinen, P. Skiold, S. McTaggart, D. Wong-Rieger, S. Campbell, R. Hill, Variation in the prices of oncology medicines across Europe and the implications for the future, Generics and Biosimilars Initiative Journal, Vol. 10, No. 2, pp. 72 - 82, Feb, 2021

• Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021-03)

  B. Godman, A. Hill, S. Simoens, G. Selke, I. Selke Krulichova, C. Zampirolli, A. Martin, W. Oortwijn, A. Timoney, L. Gustafsson, L. Vončina, H. Kwon, J. Gulbinovic, D. Gotham, J. Wale, W. da Silva, T. Bochenek, A. Kurdi, E. Allocati, O. Ogunleye, J. Meyer, I. Hoxha, A. Malaj, C. Hierlander, R. Sauremann, W. Hamelinck, G. Petrova, O. Laius, I. Langner, J. Yfantopoulos, R. Joppi, A. Jakupi, I. Greičiute-Kuprijanov, P. Vella Bonanno, H. Piepenbrink, V. de Valk, M. Wladysiuk, V. Marković Peković, I. Mardare, J. Furst, D. Tomek, M. Obach Cortadellas, C. Zara, C. Pontes, S. McTaggart, T. Laba, O. Melien, D. Wong-Rieger, S. Bae, R. Hill, Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications, Expert Review of Pharmacoeconomics & Outcome Research, Vol. 21, No. 4, pp. 527 - 540, Mar, 2021